Pharmacogenomics and Cardiovascular Events | Pharmacogenomics and Effective Treatment With Clopidogrel

Pharmacogenomics and Cardiovascular Events research study

What is the primary objective of this study?

The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.

Who is eligible to participate?

Inclusion Criteria: - Currently taking or prescribed Clopidogrel or under consideration - Acute/interventionPatients of the Avera Heart Hospital - Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute Exclusion Criteria: - Unable to provide informed consent

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Pharmacogenomics and Cardiovascular Events

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Genetic:PharmacogenomicsUtilizing pharmacogenomics to determine the most effective treatment

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

ClopidogrelPatients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment

Study Status


Start Date: June 2012

Completed Date: January 2015


Type: Observational


Primary Outcome:

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Gareth Davies, PhD

Lead Sponsor:

Collaborator: Avera Heart Hospital of South Dakota

More information:

Topol EJ, Schork NJ. Catapulting clopidogrel pharmacogenomics forward. Nat Med. 2011 Jan;17(1):40-1. doi: 10.1038/nm0111-40.

Discuss Plavix